Two spin-offs from the Paul Scherrer Institute (PSI) have made it into the TOP 100 Swiss Startups 2024!
Araris Biotech AG has secured an impressive 17th place and continues its success story. This PSI and ETH Zurich spin-off focuses on commercializing a novel antibody-drug conjugate (ADC)-linker technology. It is the sixth year in a row that Araris has been recognized by a jury of investors and startup experts.
Tandem Therapeutics, which was founded just last year, has already achieved 97th place in the TOP 100 ranking! This spin-off develops therapies that specifically target the extracellular matrix (ECM) – an often-overlooked area crucial for treating fibrotic diseases.
We warmly congratulate Philipp Spycher (CEO of Araris) and the team at Tandem Therapeutics on these outstanding achievements and look forward to supporting their continued development!
https://www.top100startups.swiss/rankings
https://www.ararisbiotech.com/
